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 Abstract:  We assessed whether alternative transcripts 
(using KLK2, KLK3 and KLK4 as models) are differen-
tially regulated by androgens and anti-androgens as an 
indicator of prostate cancers as they acquire treatment 
resistance. Using RNAseq of LNCaP cells treated with 
dihydrotestosterone, bicalutamide and enzalutamide, 
we show that the expression of variant KLK transcripts 
is markedly different to other variant transcripts at those 
loci. We also reveal that KLK variants are also over 2-fold 
more highly expressed in prostate cancers compared to 
their corresponding normal prostate. We propose that 
androgens and anti-androgens can activate specific vari-
ant transcripts of critical prostate cancer genes during 
treatment resistance. 
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 The kallikrein (KLK)-related peptidase gene family com-
prises 15 genes and forms the largest contiguous cluster of 
serine proteases in the human genome ( Gan et al., 2000 ; 
 Harvey et al., 2000 ;  Yousef et al., 2000 ). The KLKs have 
gained much interest as potential biomarkers for many 
different cancer types since their discovery ( Schmitt et al., 
2013 ). Indeed, KLK3, also known as prostate-specific 
antigen (PSA), remains the most commonly-used clini-
cal biomarker for prostate cancer. The formation of the 
 KLK gene family through gene duplication has resulted 
in a relaxation of selective pressure that has led to some 
members acquiring tissue-specific expression ( Lawrence 
et al., 2010 ).  KLK2 ,  KLK3 and  KLK4 , which are clustered 
at the centromeric end of the  KLK locus, are predomi-
nantly prostate specific, but importantly these  KLK s 
are also regulated by androgens ( Lawrence et  al., 2012 ). 
Androgens are important mediators of prostate cancer 
progression, as highlighted by the therapeutic targeting 
of the androgen receptor in men with metastatic disease. 
These clinical treatments aimed at suppressing androgen 
receptor action include gonadotropin-releasing hormone 
analogs, gonadotropin-releasing hormone antagonists, 
and anti-androgens such as bicalutamide and enzaluta-
mide ( Mitsiades, 2013 ). In this study we investigated the 
transcriptional changes at the  KLK2 ,  KLK3 and  KLK4 loci 
in prostate cancer cells (LNCaP) after treatment with an 
androgen (dihydrotestosterone, DHT), and anti-androgens 
(bicalutamide and enzalutamide) to assess whether these 
loci might be reflective of the early adaptive responses of 
prostate cancer cells as they acquire anti-androgen treat-
ment resistance. 
 The KLK-related peptidases readily express variant/
alternative transcripts ( Kurlender et  al., 2005 ). Thus, we 
have particularly focused on variant transcripts at the 
 KLK2 ,  KLK3 and  KLK4 loci that might provide information 
on novel adaptive responses, or simply reflect increased 
aberrant RNA splicing/transcription as a function of andro-
gen and anti-androgen treatments. In this study we have 
summarized unique variants at the  KLK2 ,  KLK3 and  KLK4 
loci using the UCSC gene annotation track ( http://genome.
ucsc.edu/index.html ). A ClustalW alignment of the known 
or putative proteins encoded by these variants is summa-
rized in Supplementary Figure  1. We then inspected our 
RNAseq dataset of LNCaP cells that were treated with either 
ethanol (mock), 10 n m DHT (androgen), 10  μ m bicalutamide 
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(anti-androgen) or 10  μ m enzalutamide (anti-androgen) for 
48 h by string aligning sequences that flank unique exon –
 exon splice sites of the variants ( Table 1 ). 
 There are seven variants of the  KLK2 gene (includ-
ing the full-length reference  KLK2 gene), some of which 
have missing (variants 5 and 6) or extended (variants 
4, 6 and 7) exons, while others (variants 2 and 3) have 
slight changes in exon usage at the donor – acceptor 
splice sites ( Figure 1 A). There was an overall increase 
of  KLK2 expression in LNCaP cells after bicalutamide 
J. Lai et al.: Alternative KLK transcripts      3
 Table 1   Sequences of  KLK variants used in string matching against RNAseq data. 
Variant   Sequence   Spanning exons   UCSC/ENSEMBL ID 
  #  KLK2-1   CACTTGTGGG GGTGATTCTG   exon 4 – exon 5   uc002ptv.3
  #  KLK2-2   GAGGGGAAAG GGTGATTCTG   exon 4 – exon 5   uc002ptu.3
KLK2-3   CCAGAGGAGT GAGTCTTCAG   exon 3 – exon 4   uc002ptt.3
KLK2-4   CACTTCTCAG GAATAGCCAG   exon 2 – exon 3   uc010ycl.2
  #  KLK2-5   GGGTGCACTG GAATAGCCAG   exon 1 – exon 3   uc010ycm.2
KLK2-6/7  ACCCAACATG GAAATGCTGG   intron 3   uc010eog.3 and 
uc010yck.2
  #  KLK3-1   CACCTGCTCG GGTGATTCTG   exon 4 – exon 5   uc021uyi.1
KLK3-2   CACAGGCCAG GCCAGGTGAT    exon 3 – exon 4   uc010eof.2
  #  KLK3-3   GCATCAGGAA GCCAGGTGAT   exon 2 – exon 3   uc002ptr.1
KLK3-4   CACCTGCTCG TGGGTCATTC   exon 4 – exon 5   uc002pts.1
KLK3-5   TAACTGGCTTCGGTTGTGTC   intron 2   uc002ptp.1
KLK4-1   GGTGTC[AG]CAG GA[GT]C[GT]CTCGT   exon 1 – exon 2   uc002pua.1
KLK4-2   GGTGTC[AG]CAG CTGCAGCCAA   exon 1 – exon 2   uc002puc.1
KLK4-3   CTGGCGAACG GGTGACTCTG   exon 3 – exon 5   uc002pty.1
  #  KLK4-4   TGTTTCCAGAA CTCCT[AC]CACC   exon 2 – exon 3   uc002ptz.1
KLK4-5   AGGAAGAGAGAAACAGAAAC   intron 4   uc010eoi.1
KLK4-6   TGAACTAAG CTCCT[AC]CACC   intron 2 – exon 3   uc002pud.1
GAPDH-1   GAGTCAACGG ATTTGGTCGT   exon 2 – exon 3   uc001qop.2
GAPDH-2   TCATTTCCTG GTATGACAAC   exon 8 – exon 9   uc001qop.2 
 Underline: sequence on other side of the exon – exon splice site. 
 []: SNPs that are accounted for in string matching. 
  #  Variants without unique exon – exon splice sites. Expression was determined by subtracting reads from other variants that shared exon –
 exon splice sites used in string matching. 
 Figure 1   Variant expression at the  KLK2 ,  KLK3 , and  KLK4 locus in LNCaP prostate cancer cells after treatment with ethanol (Mock), 
 bicalutamide (BIC), enzalutamide (ENZ), and androgen (DHT). 
 Cells were maintained in phenol red free RPMI-1640 supplemented with 10% charcoal stripped fetal bovine serum for 48 h, prior to treat-
ment with 100 n m (DHT) or 10  μ m (BIC, ENZ) for an additional 48 h. Total RNA was extracted for RNAseq using the Illumina HiSeq (San 
Diego, CA, USA) platform. Two or three independent RNAs for each treatment were pooled and used for RNAseq. RNAseq was carried out at 
100 bp resolution, paired-end, and strand specific. Variant expression was determined using 10 bp of sequence on both sides of unique 
splice sites ( Table 1 ), and string aligning against both pairs of unmapped RNAseq data (fastq files) using a custom Perl script. Expression 
was normalized against two exon-spanning sequences at the GAPDH locus. In some instances, reads for non-unique splice sites were 
determined by subtraction from other variants. Gene structures in (A), (C) and (E) are represented as follows: thin line = intron, medium 
line = untranslated sequence, thick line = coding sequence. The reference/wild-type  KLK transcript is indicated by the dark blue colored 
 KLK with the designated name. Variants are color coordinated in all donut and column charts. For  KLK2 , white represents both  variant 6 
and  variant 7 in donut and column charts. The red number beside donut charts indicates the magnitude of increase in expression for all 
 KLK2 ,  KLK3 or  KLK4 transcripts compared to mock treated cells. (A) Illustration of seven variant transcripts at the  KLK2 locus. The donut 
chart indicates the proportion of  KLK2 variant expression for each treatment. (B) Log-fold change in gene expression for each  KLK2 variant 
over mock treated cells. (C) Illustration of five variant transcripts at the  KLK3 locus, and the proportion of  KLK3 variant expression for each 
treatment. (D) Log-fold change in gene expression for each  KLK3 variant over mock treated cells. (E) Illustration of six variant transcripts 
at the  KLK4 locus and the proportion of  KLK4 variant expression for each treatment. (F) Log-fold change in gene expression for each  KLK4 
variant over mock treated cells. 
(4.6-fold relative to mock), enzalutamide (1.6-fold) and 
DHT (111-fold) treatments ( Figure 1 A). The proportion 
of  KLK2 variants that are expressed differed between 
the treatments ( Figure 1 A), however, due to the differ-
ent sensitivity of these variants to bicalutamide, enza-
lutamide and DHT treatments ( Figure 1 B). For example, 
 KLK2  variant 5 is the most highly regulated  KLK2 variant 
by bicalutamide, resulting in this variant comprising 
approximately two-thirds of all  KLK2 variants for this 
treatment. Despite this, the variant comprises less than 
one-third of all  KLK2 variants in cells treated with DHT, 
as  KLK2  variant 1 and  KLK2 variant 2 are equally highly 
regulated by DHT ( Figure 1 B). Conversely,  KLK2 variant 
1 is highly down-regulated by bicalutamide, resulting in 
complete loss of variant 1 expression in bicalutamide 
treated cells. Given that variant 1 is the wild-type  KLK2 
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transcript, and that  KLK2 is involved in KLK signaling 
cascades ( Yoon et  al., 2007 ), it is tempting to consider 
that  KLK2 might mediate the early regression of pros-
tate cancers in men that have undergone bicalutamide 
treatment by coordinating the action of other prostate-
specific KLKs. It is currently unclear how and why these 
variants are differentially regulated by bicalutamide, 
enzalutamide and DHT, given that they all share the 
same promoter region ( Figure 1 A). 
 Similar to  KLK2 , the  KLK3 gene is expressed as multiple 
variant transcripts ( Figure 1 C). Interestingly,  KLK3 variant 
1 (reference  KLK3 transcript) was more highly expressed 
than all other variants combined ( Figure 1 C), indicating 
that variant transcription is not as common as  KLK2 . Con-
sequently, overall  KLK3 expression was increased in LNCaP 
cells after bicalutamide (7.8-fold), enzalutamide (2.3-fold) 
and DHT (103-fold) treatments. Of the  KLK3 variants,  KLK 
variant 2 and  KLK variant 3 are evidently less regulated by 
DHT in LNCaP cells ( Figure 1 D). These variants are also the 
least responsive to enzalutamide and bicalutamide treat-
ments ( Figure 1 D). Similar to  KLK2 , all  KLK3 variants share 
the same promoter region ( Figure 1 C). 
 KLK4 is expressed as six variant transcripts 
( Figure  1 E), and similar to  KLK3 , the predominantly-
expressed  KLK4 transcript (variant 4) is more highly 
expressed than all other  KLK4 variants combined 
( Figure 1 E). The predominant expression of  KLK4 variant 
4 validates others ’ ( Korkmaz et al., 2001 ;  Xi et al., 2004 ) 
and our ( Lai et  al., 2009 ) studies that indicate that 
the reference  KLK4 transcript is not well expressed in 
prostate cancer cells. The UCSC track designates  KLK4 
variant 4 as non-protein coding ( Figure 1 E), however, 
open-reading frame analysis from the  Korkmaz et  al. 
(2001) study suggests that this variant has the capacity to 
encode a KLK4 protein that lacks the pre-pro domain that 
is required for extracellular secretion and enzyme acti-
vation. Indeed, a KLK4 variant 4 protein is further sup-
ported by the  Dong et al. (2005) , study which translated 
this variant  in vitro . It has been proposed that this pre-
dominantly expressed and truncated KLK4 variant might 
function intracellularly, and be constitutively active ( Xi 
et al., 2004 ;  Dong et al., 2005 ). Indeed, KLK4 has been 
shown to initiate intracellular signaling via protease-
activated receptors in prostate cancer cells ( Ramsay 
et al., 2008 ). Conversely, the pre-pro domain might not 
be necessary for KLK4 ’ s role in the prostate and prostate 
cancers, as a recent study proposes that catalytic activity 
of KLK4 is not needed in the prostate ( Jin et  al., 2013 ). 
 Jin et al. (2013) suggest that KLK4 ’ s function in the pros-
tate is to decrease promyelocytic leukaemia zinc finger 
stability, which results in elevated androgen receptor 
levels through a feedback circuit. It is unclear whether 
the other KLK4 variants which comprise  < 110 amino 
acids are translated, although the  Dong et  al. (2005) 
study indicates that  KLK4-3 is unlikely to function at the 
protein level as it was not readily translated  in vitro . The 
high expression of the predominant variant (variant 4) 
in LNCaP cells is not solely a function of androgen or 
anti-androgen treatments, as the magnitude of response 
for some of the other variants (variants 3, 5 and 6 for 
bicalutamide, and variants 3 and 6 for DHT) is similar 
to  KLK4 variant 4 ( Figure 1 F). Interestingly, the expres-
sion of  KLK4 variant 5 after bicalutamide treatment is 
similar to other  KLK4 variants.  KLK4 variant 5 expres-
sion, however, is evidently less expressed than other 
 KLK4 variants after DHT treatment ( Figure 1 F). This sug-
gests that androgen receptor agonists and antagonists 
may be able to selectively regulate variant transcription 
at particular loci. Furthermore,  KLK4 variants 3 ,  4 and  5 
share similar promoter regions, but  variants 3 and  4 are 
more responsive to DHT treatment compared to  variant 
5 . Coupled with similar observations for  KLK2 and  KLK3 
variants, this indicates that the androgen regulation of 
 KLK variants might also be conferred after transcription. 
Furthermore, the relative expression of the predomi-
nantly-expressed  KLK variants from DHT-treated LNCaP 
cells is similarly predominantly expressed in the VCAP 
prostate cancer cell line, which is both androgen recep-
tor- and ERG-positive, indicating that some of the mecha-
nisms mediating variant expression are likely common 
between prostate cancer cells (Supplementary Figure 2). 
 Given the differences in the regulation of  KLK2 ,  KLK3 
and  KLK4 variants by androgens and therapeutic anti-
androgens, we then inspected the  Ren et al. (2012) RNAseq 
dataset of 14 prostate cancers and their corresponding 
normal prostate RNA to assess whether  KLK2 ,  KLK3 and 
 KLK4 variants might also be differentially expressed in 
prostate cancer compared to normal prostate cells. We 
found that  KLK2 variants 6 and/or  7 are over 2-fold more 
highly expressed in nine out of the 14 prostate cancers 
compared to the normal prostate cells ( Figure 2 ).  KLK2 
variant 3 is also over 2-fold more highly expressed in six 
out of 14 prostate cancers ( Figure 2 ). Both  KLK3 variant 5 
and  KLK4 variant 5 are over 2-fold more highly expressed 
in ten out of 14 prostate cancers compared to normal 
prostate cells ( Figure 2 ). Interestingly,  KLK3 variant 5 is 
the most regulated  KLK3 variant by bicalutamide and 
DHT, and  KLK4 variant 5 is similarly highly regulated by 
bicalut amide and DHT compared to other  KLK4 variants. 
The lack of co-expression profiles for  KLK variant tran-
scripts at their respective loci indicates that variant tran-
scripts originating from the same locus (which potentially 
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use the same promoter region) are somehow selected for 
by prostate cancer cells. 
 To conclude, we have carried out a pilot study on 
alternative transcription as a function of androgen and 
therapeutic anti-androgens using prostate-specific, and 
androgen-regulated  KLK genes ( KLK2 ,  KLK3 and  KLK4 ) as 
a model. We show that some variants of the  KLK2 ,  KLK3 
and  KLK4 genes are differentially regulated by androgens 
and therapeutic anti-androgens, and consider whether 
they might have utility to predict treatment-resistant phe-
notypes. We also report that some  KLK variants might 
be over-expressed in prostate cancer tissue compared to 
normal prostate. Given the great variability of the expres-
sion levels in some samples and the very small number of 
specimens examined, however, it is at present not clear 
whether the variants are differentially expressed in cancer 
compared with normal tissue, and further research is 
therefore required. Thus, we propose further investigation 
to assess whether these variants might have better efficacy 
for prostate cancer screening and/or prediction of treat-
ment resistance, possibly using an index that is derived 
from multiple  KLK variants. 
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